

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

COX ET AL

Serial Number: To be assigned

Group Art Unit: To be assigned

Filed: June 14, 2005

Examiner: To be assigned

For: MASTITIS TREATMENT

Priority Document: PCT/EP2003/014051 filed December 10, 2003

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Honorable Assistant Commissioner of Patents
Alexandria, VA 22313

June 14, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08B. These references were cited in the International Search Report. Copies of the Search Report and cited references are enclosed.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can deter-

mine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,



William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Intervet U.S.
Patent Department
29160 Intervet Lane
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4317
Fax: (302) 934-4305

#2

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number To be assigned

Filing Date June 14, 2005

First Named Inventor COX, Peter et al.

Art Unit To be assigned

Examiner Name To be assigned

Sheet

1

of

1

Attorney Docket Number I-2002.024 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LOHUIS, J.A.C.M. ET AL: "Effect of Steroidal Anti-Inflammatory Drugs on Escherichia Coli ..." J. of Dairy Science, (Jan. 1989) Amer. Dairy Science Assoc. V72, N1, p241-249	
		FARNSWORTH, R.J. ET AL: "The Effect of Penicillin, Dihydrostreptomycin and Prednisolone Treatment ..." Canadian J. of Comparative Medicine-Review, (July 1975) V39, N3 p 340-348	
		FAULL, W.B. ET AL: "Treatment of clinical mastitis: Two intramammary formulations compared" Veterinary Record, British Veterinary Assoc.(Feb. 8, 1975) V96, N6 p127-129	
		HORNISH, R.E. ET AL: "Cephalosporins in Veterinary Medicine-Ceftiofur Use in Food ..." (July 2002) Current Topics in Medicinal Chemistry, Bentham Sci. Pub. V2, N7, p 717-731, NL	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Express Mail: EV 630722958 US